Nama's AI scorecard currently rates Koninklijke Philips Hold (5.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PHG's P/E ratio?

Koninklijke Philips trades at a trailing price-to-earnings ratio of 15.2.

When does PHG report earnings?

Koninklijke Philips's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $0.61.

What is the PHG price target?

The median analyst price target from 5 analysts is $29.50, with a range of $26.20 – $41.00.

Is PHG Shariah compliant?

Nama's AAOIFI-style screen reads Koninklijke Philips as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Does PHG pay a dividend?

Yes — Koninklijke Philips's dividend yield is 3.3%.

Nama Insights

Koninklijke Philips (PHG)

Healthcare · Medical Devices · NYSE

Koninklijke Philips (PHG) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $29.67B, a trailing price-to-earnings ratio of 15.2 and a free-cash-flow yield of 1.9%. Over the most recent reported fiscal year, revenue declined 1.0% and free cash flow per share fell 45.3%. Nama's AI scorecard rates it Hold, 5.6 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Hold · 5.6/10

The sections balance. As of Nov 7, 2026.

Momentum

Trailing · -14.7% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-37.2%

How far the last close sits under the highest price of the past five years.

Market cap	$29.67B
Trailing P/E	15.2
Price / book	2.3
Price / sales	1.5
FCF yield	1.9%
Dividend yield	3.3%
Gross margin	45.9%
Operating margin	9.9%
Net margin	6.3%
Revenue growth (YoY)	-1.0%
Revenue growth (3-yr annual)	+0.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	-45.3%
Beta	0.9
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

PHG earnings

Next report: Feb 9, 2027 (Q4 2026, EPS estimate $0.61). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$0.45	$0.36	+25.0%	$4.90B
Q2 2026	Jul 26, 2026	$0.56	$0.37	+51.4%	$4.86B
Q1 2026	May 5, 2026	$0.27	$0.19	+42.1%	$4.36B
Q4 2025	Feb 9, 2026	$0.71	$0.50	+42.0%	$5.69B

PHG analyst price target

Median target $29.50 from 5 analysts, ranging $26.20 – $41.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
DXCM	DexCom	$29.62B	29.7
STE	STERIS	$24.60B	23.2

Explore live PHG data on Nama Insights →

Recent Congressional trades

Koninklijke Philips trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Earl Blumenauer	House	Buy	$1,001 - $15,000	Mar 2, 2024

PHG FAQ

Is PHG a buy?: Nama's AI scorecard currently rates Koninklijke Philips Hold (5.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PHG's P/E ratio?: Koninklijke Philips trades at a trailing price-to-earnings ratio of 15.2.
When does PHG report earnings?: Koninklijke Philips's next scheduled report is on Feb 9, 2027. Analysts expect EPS of $0.61.
What is the PHG price target?: The median analyst price target from 5 analysts is $29.50, with a range of $26.20 – $41.00.
Is PHG Shariah compliant?: Nama's AAOIFI-style screen reads Koninklijke Philips as Not Shariah Compliant. At least one of the three ratios or the industry test failed.
Does PHG pay a dividend?: Yes — Koninklijke Philips's dividend yield is 3.3%.